A compound of general formula wherein: R 1 and R 2 are different or the same and are independently selected from the group consisting of hydrogen, methyl, ethyl, difluoromethyl, cyclopropylmethyl or cyclopropyl; R 3 are the same two chlorine atoms in position 3 and 5 of the pyridyl ring; Z is a group (CH 2) m wherein m = 0; A is a phenyl ring, which is optionally substituted by one or more substituents R 4, which may be the same or different and are independently selected from the group consisting of: linear or branched (C 1 -C 2) alkyl optionally substituted by one or more (C 3 -C 7)heterocycloalkyl and preferably 4-morpholinyl; trifluoromethyl; methylthio; halogen selected from fluoro or chloro; and OR 7 wherein R 7 is selected from the group consisting of -H; - (C 1 -C 4) alkyl optionally substituted by a radical selected from OH, cyclopropyl, 4-morpholinyl, 1- or 4-piperidinyl, 4-pyridinyl and phenyl; - trifluoromethyl or difluoromethyl; and W is the group -NR 9 SO 2 R 10 wherein R 9 is selected in the group consisting of (C 1 -C 4) alkyl optionally substituted by 4-morpholinyl, 1-piperidinyl, 1-pyrrolidinyl, piperazinyl, 1,2-thiazolidin-3-yl, piperazin-1-ylcarbonyl wherein any such ring may be optionally substituted by one or more methyl, ethyl or OH; and R 11 R 12 N-(C 1 -C 3)alkylene wherein R 11 and R 12 are independently H or methyl optionally substituted by a group OH; and R 10 is selected in the group consisting of (C 1 -C 4) alkyl optionally substituted by (C 3 -C 7) cycloalkyl and (C 3 -C 7) cycloalkyl; their N-oxides on the pyridine ring, and pharmaceutically acceptable salts thereof. R 1 and R 2 are different or the same and are independently selected from the group consisting of hydrogen, methyl, ethyl, difluoromethyl, cyclopropylmethyl or cyclopropyl; R 3 are the same two chlorine atoms in position 3 and 5 of the pyridyl ring; Z is a group (CH 2) m wherein m = 0; A is a phenyl ring, which is optionally substituted by one or more substituents R 4, which may be the same or different and are independently selected from the group consisting of: linear or branched (C 1 -C 2) alkyl optionally substituted by one or more (C 3 -C 7)heterocycloalkyl and preferably 4-morpholinyl; trifluoromethyl; methylthio; halogen selected from fluoro or chloro; and OR 7 wherein R 7 is selected from the group consisting of -H; - (C 1 -C 4) alkyl optionally substituted by a radical selected from OH, cyclopropyl, 4-morpholinyl, 1- or 4-piperidinyl, 4-pyridinyl and phenyl; - trifluoromethyl or difluoromethyl; and linear or branched (C 1 -C 2) alkyl optionally substituted by one or more (C 3 -C 7)heterocycloalkyl and preferably 4-morpholinyl; trifluoromethyl; methylthio; halogen selected from fluoro or chloro; and OR 7 wherein R 7 is selected from the group consisting of -H; - (C 1 -C 4) alkyl optionally substituted by a radical selected from OH, cyclopropyl, 4-morpholinyl, 1- or 4-piperidinyl, 4-pyridinyl and phenyl; - trifluoromethyl or difluoromethyl; and W is the group -NR 9 SO 2 R 10 wherein R 9 is selected in the group consisting of (C 1 -C 4) alkyl optionally substituted by 4-morpholinyl, 1-piperidinyl, 1-pyrrolidinyl, piperazinyl, 1,2-thiazolidin-3-yl, piperazin-1-ylcarbonyl wherein any such ring may be optionally substituted by one or more methyl, ethyl or OH; and R 11 R 12 N-(C 1 -C 3)alkylene wherein R 11 and R 12 are independently H or methyl optionally substituted by a group OH; and R 10 is selected in the group consisting of (C 1 -C 4) alkyl optionally substituted by (C 3 -C 7) cycloalkyl and (C 3 -C 7) cycloalkyl; their N-oxides on the pyridine ring, and pharmaceutically acceptable salts thereof.